HRP20150479T1 - Multimeriäśna multiepitopska cjepiva protiv influence - Google Patents

Multimeriäśna multiepitopska cjepiva protiv influence Download PDF

Info

Publication number
HRP20150479T1
HRP20150479T1 HRP20150479TT HRP20150479T HRP20150479T1 HR P20150479 T1 HRP20150479 T1 HR P20150479T1 HR P20150479T T HRP20150479T T HR P20150479TT HR P20150479 T HRP20150479 T HR P20150479T HR P20150479 T1 HRP20150479 T1 HR P20150479T1
Authority
HR
Croatia
Prior art keywords
seq
corresponds
polypeptide according
group
vaccine
Prior art date
Application number
HRP20150479TT
Other languages
English (en)
Inventor
Tamar Ben-Yedidia
Yossi Singer
Original Assignee
Biondvax Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondvax Pharmaceuticals Ltd. filed Critical Biondvax Pharmaceuticals Ltd.
Publication of HRP20150479T1 publication Critical patent/HRP20150479T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (10)

1. Multimerični multiepitopni polipeptid koji sadrži više kopija više epitopa peptida virusa influence organizirane u konfiguraciju odabranu iz naizmjeničnih sekvencijalnih polimeričnih struktura (X1X2X3..X9)n i bloka kopolimerne strukture (X1)n(X2)n(X3)n...(X9)n, pri čemu je n u svakom pojavljivanju neovisno cjelina od 3-5; i svaki od X1-X9 je različiti epitop virusa influence odabran iz skupine koja se sastoji od HA 354-372 koji odgovara E1 i SEQ ID BR: 82, HA 91-108 odgovara E2 i SEQ ID BR: 48, M1 2-12 odgovara E3 i SEQ ID BR: 25, HA 150-159 odgovara E4 i SEQ ID BR: 52, HA 143-149 odgovara E5 i SEQ ID BR: 51, NP 206-229 odgovara E6 i SEQ ID BR: 64, HA 307-319 odgovara E7, i SEQ ID BR: 59, NP 335-350 odgovara E8 i SEQ ID BR: 69, i NP 380-393 odgovara E9 i SEQ ID BR: 70.
2. Polipeptid sukladno Zahtjevu 1 koji sadrži: (i) Devet različitih epitopa peptida virusa influence organizirane u sljedeću izmjeničnu sekvencijalnu polimeričnu strukturu [E1E2E3E4E5E6E7E8E9]n, pri čemu je n 3 ili 5; ili (ii) Tri ponavljanja od devet različitih epitopa peptida virusa influence organizirana u sljedeću blok kopolimernu strukturu [E1E1E1-E2E2E2-E3E3E3-E4E4E4-E5E5E5-E6E6E6-E7E7E7-E8E8E8-E9E9E9].
3. Polipeptid sukladno Zahtjevu 1 kako je naznačeno u sekvenci odabranoj iz grupe koja sadrži SEQ ID BR:84, SEQ ID BR:86 i SEQ ID BR:88.
4. Polipeptid sukladno Zahtjevu 1 koji nadalje sadrži niz nosača.
5. Izolirani polinukleotid koji kodira multiepitopni polipeptid influence sukladno bilo kojem od Zahtjeva 1-3.
6. Izolirani polinukleotid sukladno Zahtjevu 5 koji kodira niz polipeptida odabran iz grupe koja sadrži: SEQ ID BR:84, SEQ ID BR:86, i SEQ ID BR:88; ili sadrži niz odabran iz grupe koja se sastoji od SEQ ID BR:83, SEQ ID BR:85, i SEQ ID BR:87.
7. Cjepivo za imunizaciju protiv influence koje sadrži barem jedan polipeptid sukladno Zahtjevu 1.
8. Cjepivo sukladno Zahtjevu 7, nadalje sadrži katalizator.
9. Cjepivo sukladno bilo kojem od Zahtjeva 7 ili 8 za upotrebu u izazivanju imunološkog odgovora i omogućavanje zaštite protiv influence.
10. Upotreba polipeptida sukladno bilo kojem od zahtjeva 1-4 za pripremu kompozicije cjepiva za imunizaciju protiv influence.
HRP20150479TT 2007-08-02 2015-05-04 Multimeriäśna multiepitopska cjepiva protiv influence HRP20150479T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02
PCT/IL2008/001062 WO2009016639A2 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines
EP08789738.5A EP2173376B1 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines

Publications (1)

Publication Number Publication Date
HRP20150479T1 true HRP20150479T1 (hr) 2015-07-17

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150479TT HRP20150479T1 (hr) 2007-08-02 2015-05-04 Multimeriäśna multiepitopska cjepiva protiv influence

Country Status (18)

Country Link
US (2) US8747861B2 (hr)
EP (1) EP2173376B1 (hr)
JP (1) JP5654345B2 (hr)
KR (1) KR101580660B1 (hr)
CN (1) CN101795709B (hr)
AU (1) AU2008281384C1 (hr)
BR (1) BRPI0815008B8 (hr)
CA (1) CA2695399C (hr)
DK (1) DK2173376T3 (hr)
EA (1) EA017887B1 (hr)
ES (1) ES2539818T3 (hr)
HK (1) HK1142809A1 (hr)
HR (1) HRP20150479T1 (hr)
HU (1) HUE025149T2 (hr)
MX (1) MX2010001284A (hr)
PL (1) PL2173376T3 (hr)
PT (1) PT2173376E (hr)
WO (1) WO2009016639A2 (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
JP2011519828A (ja) 2008-04-18 2011-07-14 バクシネート コーポレーション フラジェリンの欠失変異体と使用方法
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5805195B2 (ja) 2010-08-23 2015-11-04 カンステム バイオテック カンパニー リミテッド Ｎｏｄ２アゴニストで処理した幹細胞またはその培養物を含む免疫疾患および炎症性疾患の予防および治療用の薬学的組成物
EP2678361A4 (en) * 2011-02-21 2015-06-03 Vaxinnate Corp COMPOSITIONS WITH IMPROVED IMMUNOGENICITY AND / OR REDUCED REACTIVITY AND METHOD OF USE THEREOF
CA2828068C (en) * 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
AU2012273039B2 (en) * 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
ES2490915B1 (es) * 2011-09-12 2015-09-17 Laboratorios Del Dr. Esteve, S.A. Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos
CA3207612A1 (en) * 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US20150056231A1 (en) * 2012-04-02 2015-02-26 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
EP3125931A4 (en) * 2014-04-03 2017-09-20 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
RU2769406C2 (ru) * 2016-02-03 2022-03-31 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
WO2018126060A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US20220118077A1 (en) * 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
CA3167318A1 (en) * 2020-02-14 2021-08-19 Neil P. King Polypeptides, compositions, and their use to treat or limit development of an infection
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
PL170980B1 (pl) * 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
AU5128493A (en) * 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Recombinant multivalent m protein vaccine
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) * 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5977081A (en) * 1997-05-20 1999-11-02 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
ES2298316T3 (es) * 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
CN1306438A (zh) 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2003509465A (ja) 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
WO2001024810A1 (en) 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
BRPI0111830B8 (pt) 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
US7108679B2 (en) * 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
CA2589556A1 (en) * 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
KR20080027777A (ko) * 2005-06-01 2008-03-28 배리에이션 바이오테크놀로지스 아이엔씨. 펩티드­기초 인플루엔자 백신 제제
US7260958B2 (en) * 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
EP1945253A2 (en) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
AU2006322907B2 (en) * 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
AU2007300663A1 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
JP2010536878A (ja) 2007-08-21 2010-12-02 ダイナバックス テクノロジーズ コーポレイション インフルエンザタンパク質を製造および使用する組成物および方法

Also Published As

Publication number Publication date
CN101795709B (zh) 2013-07-17
US8747861B2 (en) 2014-06-10
WO2009016639A2 (en) 2009-02-05
JP2010535026A (ja) 2010-11-18
EP2173376B1 (en) 2015-03-25
AU2008281384A1 (en) 2009-02-05
HK1142809A1 (en) 2010-12-17
PL2173376T3 (pl) 2015-08-31
CA2695399C (en) 2017-10-17
PT2173376E (pt) 2015-07-30
CN101795709A (zh) 2010-08-04
EA017887B1 (ru) 2013-03-29
WO2009016639A3 (en) 2009-04-30
AU2008281384B2 (en) 2012-02-16
MX2010001284A (es) 2010-08-31
EP2173376A2 (en) 2010-04-14
KR101580660B1 (ko) 2015-12-28
EA201070219A1 (ru) 2010-08-30
JP5654345B2 (ja) 2015-01-14
ES2539818T3 (es) 2015-07-06
US20110182974A1 (en) 2011-07-28
DK2173376T3 (en) 2015-06-29
BRPI0815008B1 (pt) 2019-11-19
CA2695399A1 (en) 2009-02-05
US9353159B2 (en) 2016-05-31
BRPI0815008B8 (pt) 2021-05-25
US20140286982A1 (en) 2014-09-25
HUE025149T2 (hu) 2016-01-28
KR20100045473A (ko) 2010-05-03
AU2008281384C1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
HRP20150479T1 (hr) Multimeriäśna multiepitopska cjepiva protiv influence
JP2010535026A5 (hr)
HRP20190907T1 (hr) Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
HRP20200285T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom
JP2009523422A5 (hr)
JP2014507146A5 (hr)
JP2012527899A5 (hr)
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
Liu et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
JP2009544318A5 (hr)
JP2013520172A5 (hr)
JP2009544333A5 (hr)
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
FI3539565T3 (fi) Koostumuksia ja menetelmiä dengue-viruksen kimeerisille rakenteille rokotteissa
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
WO2011094357A3 (en) Repiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
RU2012140741A (ru) Композиции рекомбинантного cdv и ее применение
JP2010088434A5 (hr)
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
DE602005018615D1 (de) Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie